Tier 3 — preclinical

Apigenin for Depression and Anxiety: A Systematic Review of Preclinical Studies

Jin Wang, Kun Shi
Iranian Journal of Pharmaceutical Research 2026 25(1):e167153

Bibliography

PubMed
PMID 42488186
PubMed Central
PMC13389377
DOI
10.5812/ijpr-167153

Study snapshot

DesignSystematic review of preclinical studies
ModelRodent models of depression and anxiety
Sample
InterventionApigenin across preclinical anxiety and depression models
Duration
EndpointsAnxiety-like behavior; Depression-like behavior; Neuroinflammation; Oxidative stress; Neurotransmitter and signaling pathways

What the study showed, in plain terms

This 2026 systematic review maps the animal evidence for apigenin in depression- and anxiety-related models.

Key findings

Across rodent studies, apigenin frequently improved behavioral measures and affected neuroinflammatory, oxidative-stress and neurotransmitter pathways.

What this study can and cannot tell us

All included evidence was preclinical. The review cannot establish that isolated apigenin treats depression or anxiety in humans.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology